ArticleThe New England journal of medicine2023
Increasing Prevalence of Artemisinin-Resistant HRP2-Negative Malaria in Eritrea.
Registry-linked trialOpen access · greenAbstract read
In one paragraph
Article in The New England journal of medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07527182 (Confirmation of Artemisinin Partial Resistance in Plasmodium Falciparum Using WHO Criteria), which is not on this map. Cited by 130 papers, 8 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
130citing papers in PubMed, 8 pooled it
54.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Confirmation of Artemisinin Partial Resistance in Plasmodium Falciparum Using WHO Criteria: A Multisite Clinical, Molecular and Phenotypic Study Across Five Sentinel Sites in Ethiopia, 2024-2025
Who cites it
130 citing papers in PubMed, 8 syntheses or guidelines pooled it, 188 citations in OpenAlex.
- Spatio-temporal trends of the prevalence of Plasmodium falciparum antimalarial drug resistance markers across sub-Saharan Africa from 2010 to 2024: a systematic review and meta-analysis.BMC infectious diseases · 2026Pooled it
- Incidence of kelch13 and Pfmdr1 gene mutations associated with antimalarial drug resistance in Plasmodium falciparum isolates from Ethiopia: a systematic review and meta-analysis.BMC infectious diseases · 2026Pooled it
- Artemisinin-Based Combination Therapies in East Africa: A Systematic Review of Quality, Clinical Efficacy, and Regulatory Progress Towards Sustainable Malaria Control.Tropical medicine & international health : TM & IH · 2026Pooled it
- Pooled it
- Genetic diversity, population structure, and drug resistance of Plasmodium falciparum in Kenya: a systematic review and meta-analysis.Malaria journal · 2025Pooled it
- Spatio-temporal trends of artemisinin-based combination therapy efficacy from 2010 to 2024 in sub-Saharan Africa: a systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- Single low-dose primaquine for malaria control in Africa: a systematic review of safety, efficacy and implementation barriers.BMJ global health · 2025Pooled it
- The burden of malaria in East Africa: prevalence, risk factors, and control strategies.Malaria journal · 2025Pooled it
- Rapid multiplexed nanopore amplicon sequencing to distinguish Plasmodium falciparum recrudescence from new infection in antimalarial drug trials.Scientific reports · 2025Trial
- Trial
- Bioequivalence of a new coated 15 mg primaquine formulation for malaria elimination.Malaria journal · 2024Trial
- Persistent and multiclonal malaria parasite dynamics despite extended artemether-lumefantrine treatment in children.Nature communications · 2024Trial
- Subcutaneous Administration of a Monoclonal Antibody to Prevent Malaria.The New England journal of medicine · 2024Trial
- The effect of an anti-malarial herbal remedy, Maytenus senegalensis, on electrocardiograms of healthy Tanzanian volunteers.Malaria journal · 2024Trial
- Efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine and prevalence of molecular markers of anti-malarial drug resistance in children in Togo in 2021.Malaria journal · 2024Trial
- Factors affecting haemoglobin dynamics in African children with acute uncomplicated Plasmodium falciparum malaria treated with single low-dose primaquine or placebo.BMC medicine · 2023Trial
- Asymptomatic malaria: a hidden reservoir for the transmission and circulation of artemisinin partial-resistantEmerging microbes & infections · 2026Article
- Genomic profiling of drug resistance markers in Plasmodium falciparum samples from the Democratic Republic of the Congo (2017) and Tanzania (2020-2021).The Journal of antimicrobial chemotherapy · 2026Article
- Emergence and spread of Plasmodium falciparum PX1 polymorphisms associated with decreased susceptibility to antimalarials in Uganda.Nature medicine · 2026Article
- Genomic surveillance reveals co-occurrence of Plasmodium falciparum drug resistance variants across diverse transmission settings in Ethiopia.Nature microbiology · 2026Article
70 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
16 authors at 2 institutions in 5 countries.
Selam MihreteabFrom the National Malaria Control Program (S.M.) and the Communicable Diseases Control Division (A.B.), Ministry of Health, and the World Health Organization (A.Z.K.) - both in Asmara, Eritrea; the Malaria Genetic and Resistance Unit, INSERM Unité 1201 (L.P., N.P., E.L., D.M.), the Malaria Parasite Biology and Vaccines Unit (L.P., E.L. D.M.), the Bioinformatics and Biostatistics Hub (P.C., A.C.), and the Biomics Platform, Center for Technological Resources and Research (L.M.), Institut Pasteur, Université Paris Cité, and Collège Ecole Doctorale Complexité du Vivant, Sorbonne Université (L.P.), Paris, and the Institute of Parasitology and Tropical Diseases, Dynamics of Host-Pathogen Interactions, Université de Strasbourg (C.D.-L., D.M.), and the Laboratory of Parasitology and Medical Mycology, Centre Hospitalier Universitaire Strasbourg (D.M.), Strasbourg - all in France; the Department of Microbiology and Immunology (B.H.S., K.E.W., D.A.F.) and the Center for Malaria Therapeutics and Antimicrobial Resistance, Division of Infectious Diseases, Department of Medicine (D.A.F.), Columbia University Irving Medical Center, New York; the School of Public Health and Social Medicine, Gothenburg University, Gothenburg, Sweden (M.W.); and the Global Malaria Program, World Health Organization, Geneva (P.R.).
Lucien PlatonFrom the National Malaria Control Program (S.M.) and the Communicable Diseases Control Division (A.B.), Ministry of Health, and the World Health Organization (A.Z.K.) - both in Asmara, Eritrea; the Malaria Genetic and Resistance Unit, INSERM Unité 1201 (L.P., N.P., E.L., D.M.), the Malaria Parasite Biology and Vaccines Unit (L.P., E.L. D.M.), the Bioinformatics and Biostatistics Hub (P.C., A.C.), and the Biomics Platform, Center for Technological Resources and Research (L.M.), Institut Pasteur, Université Paris Cité, and Collège Ecole Doctorale Complexité du Vivant, Sorbonne Université (L.P.), Paris, and the Institute of Parasitology and Tropical Diseases, Dynamics of Host-Pathogen Interactions, Université de Strasbourg (C.D.-L., D.M.), and the Laboratory of Parasitology and Medical Mycology, Centre Hospitalier Universitaire Strasbourg (D.M.), Strasbourg - all in France; the Department of Microbiology and Immunology (B.H.S., K.E.W., D.A.F.) and the Center for Malaria Therapeutics and Antimicrobial Resistance, Division of Infectious Diseases, Department of Medicine (D.A.F.), Columbia University Irving Medical Center, New York; the School of Public Health and Social Medicine, Gothenburg University, Gothenburg, Sweden (M.W.); and the Global Malaria Program, World Health Organization, Geneva (P.R.).
Araia BerhaneFrom the National Malaria Control Program (S.M.) and the Communicable Diseases Control Division (A.B.), Ministry of Health, and the World Health Organization (A.Z.K.) - both in Asmara, Eritrea; the Malaria Genetic and Resistance Unit, INSERM Unité 1201 (L.P., N.P., E.L., D.M.), the Malaria Parasite Biology and Vaccines Unit (L.P., E.L. D.M.), the Bioinformatics and Biostatistics Hub (P.C., A.C.), and the Biomics Platform, Center for Technological Resources and Research (L.M.), Institut Pasteur, Université Paris Cité, and Collège Ecole Doctorale Complexité du Vivant, Sorbonne Université (L.P.), Paris, and the Institute of Parasitology and Tropical Diseases, Dynamics of Host-Pathogen Interactions, Université de Strasbourg (C.D.-L., D.M.), and the Laboratory of Parasitology and Medical Mycology, Centre Hospitalier Universitaire Strasbourg (D.M.), Strasbourg - all in France; the Department of Microbiology and Immunology (B.H.S., K.E.W., D.A.F.) and the Center for Malaria Therapeutics and Antimicrobial Resistance, Division of Infectious Diseases, Department of Medicine (D.A.F.), Columbia University Irving Medical Center, New York; the School of Public Health and Social Medicine, Gothenburg University, Gothenburg, Sweden (M.W.); and the Global Malaria Program, World Health Organization, Geneva (P.R.).
Barbara H StokesFrom the National Malaria Control Program (S.M.) and the Communicable Diseases Control Division (A.B.), Ministry of Health, and the World Health Organization (A.Z.K.) - both in Asmara, Eritrea; the Malaria Genetic and Resistance Unit, INSERM Unité 1201 (L.P., N.P., E.L., D.M.), the Malaria Parasite Biology and Vaccines Unit (L.P., E.L. D.M.), the Bioinformatics and Biostatistics Hub (P.C., A.C.), and the Biomics Platform, Center for Technological Resources and Research (L.M.), Institut Pasteur, Université Paris Cité, and Collège Ecole Doctorale Complexité du Vivant, Sorbonne Université (L.P.), Paris, and the Institute of Parasitology and Tropical Diseases, Dynamics of Host-Pathogen Interactions, Université de Strasbourg (C.D.-L., D.M.), and the Laboratory of Parasitology and Medical Mycology, Centre Hospitalier Universitaire Strasbourg (D.M.), Strasbourg - all in France; the Department of Microbiology and Immunology (B.H.S., K.E.W., D.A.F.) and the Center for Malaria Therapeutics and Antimicrobial Resistance, Division of Infectious Diseases, Department of Medicine (D.A.F.), Columbia University Irving Medical Center, New York; the School of Public Health and Social Medicine, Gothenburg University, Gothenburg, Sweden (M.W.); and the Global Malaria Program, World Health Organization, Geneva (P.R.).
Marian WarsameFrom the National Malaria Control Program (S.M.) and the Communicable Diseases Control Division (A.B.), Ministry of Health, and the World Health Organization (A.Z.K.) - both in Asmara, Eritrea; the Malaria Genetic and Resistance Unit, INSERM Unité 1201 (L.P., N.P., E.L., D.M.), the Malaria Parasite Biology and Vaccines Unit (L.P., E.L. D.M.), the Bioinformatics and Biostatistics Hub (P.C., A.C.), and the Biomics Platform, Center for Technological Resources and Research (L.M.), Institut Pasteur, Université Paris Cité, and Collège Ecole Doctorale Complexité du Vivant, Sorbonne Université (L.P.), Paris, and the Institute of Parasitology and Tropical Diseases, Dynamics of Host-Pathogen Interactions, Université de Strasbourg (C.D.-L., D.M.), and the Laboratory of Parasitology and Medical Mycology, Centre Hospitalier Universitaire Strasbourg (D.M.), Strasbourg - all in France; the Department of Microbiology and Immunology (B.H.S., K.E.W., D.A.F.) and the Center for Malaria Therapeutics and Antimicrobial Resistance, Division of Infectious Diseases, Department of Medicine (D.A.F.), Columbia University Irving Medical Center, New York; the School of Public Health and Social Medicine, Gothenburg University, Gothenburg, Sweden (M.W.); and the Global Malaria Program, World Health Organization, Geneva (P.R.).
Pascal CampagneFrom the National Malaria Control Program (S.M.) and the Communicable Diseases Control Division (A.B.), Ministry of Health, and the World Health Organization (A.Z.K.) - both in Asmara, Eritrea; the Malaria Genetic and Resistance Unit, INSERM Unité 1201 (L.P., N.P., E.L., D.M.), the Malaria Parasite Biology and Vaccines Unit (L.P., E.L. D.M.), the Bioinformatics and Biostatistics Hub (P.C., A.C.), and the Biomics Platform, Center for Technological Resources and Research (L.M.), Institut Pasteur, Université Paris Cité, and Collège Ecole Doctorale Complexité du Vivant, Sorbonne Université (L.P.), Paris, and the Institute of Parasitology and Tropical Diseases, Dynamics of Host-Pathogen Interactions, Université de Strasbourg (C.D.-L., D.M.), and the Laboratory of Parasitology and Medical Mycology, Centre Hospitalier Universitaire Strasbourg (D.M.), Strasbourg - all in France; the Department of Microbiology and Immunology (B.H.S., K.E.W., D.A.F.) and the Center for Malaria Therapeutics and Antimicrobial Resistance, Division of Infectious Diseases, Department of Medicine (D.A.F.), Columbia University Irving Medical Center, New York; the School of Public Health and Social Medicine, Gothenburg University, Gothenburg, Sweden (M.W.); and the Global Malaria Program, World Health Organization, Geneva (P.R.).
Alexis CriscuoloFrom the National Malaria Control Program (S.M.) and the Communicable Diseases Control Division (A.B.), Ministry of Health, and the World Health Organization (A.Z.K.) - both in Asmara, Eritrea; the Malaria Genetic and Resistance Unit, INSERM Unité 1201 (L.P., N.P., E.L., D.M.), the Malaria Parasite Biology and Vaccines Unit (L.P., E.L. D.M.), the Bioinformatics and Biostatistics Hub (P.C., A.C.), and the Biomics Platform, Center for Technological Resources and Research (L.M.), Institut Pasteur, Université Paris Cité, and Collège Ecole Doctorale Complexité du Vivant, Sorbonne Université (L.P.), Paris, and the Institute of Parasitology and Tropical Diseases, Dynamics of Host-Pathogen Interactions, Université de Strasbourg (C.D.-L., D.M.), and the Laboratory of Parasitology and Medical Mycology, Centre Hospitalier Universitaire Strasbourg (D.M.), Strasbourg - all in France; the Department of Microbiology and Immunology (B.H.S., K.E.W., D.A.F.) and the Center for Malaria Therapeutics and Antimicrobial Resistance, Division of Infectious Diseases, Department of Medicine (D.A.F.), Columbia University Irving Medical Center, New York; the School of Public Health and Social Medicine, Gothenburg University, Gothenburg, Sweden (M.W.); and the Global Malaria Program, World Health Organization, Geneva (P.R.).
Laurence MaFrom the National Malaria Control Program (S.M.) and the Communicable Diseases Control Division (A.B.), Ministry of Health, and the World Health Organization (A.Z.K.) - both in Asmara, Eritrea; the Malaria Genetic and Resistance Unit, INSERM Unité 1201 (L.P., N.P., E.L., D.M.), the Malaria Parasite Biology and Vaccines Unit (L.P., E.L. D.M.), the Bioinformatics and Biostatistics Hub (P.C., A.C.), and the Biomics Platform, Center for Technological Resources and Research (L.M.), Institut Pasteur, Université Paris Cité, and Collège Ecole Doctorale Complexité du Vivant, Sorbonne Université (L.P.), Paris, and the Institute of Parasitology and Tropical Diseases, Dynamics of Host-Pathogen Interactions, Université de Strasbourg (C.D.-L., D.M.), and the Laboratory of Parasitology and Medical Mycology, Centre Hospitalier Universitaire Strasbourg (D.M.), Strasbourg - all in France; the Department of Microbiology and Immunology (B.H.S., K.E.W., D.A.F.) and the Center for Malaria Therapeutics and Antimicrobial Resistance, Division of Infectious Diseases, Department of Medicine (D.A.F.), Columbia University Irving Medical Center, New York; the School of Public Health and Social Medicine, Gothenburg University, Gothenburg, Sweden (M.W.); and the Global Malaria Program, World Health Organization, Geneva (P.R.).
Nathalie PetiotFrom the National Malaria Control Program (S.M.) and the Communicable Diseases Control Division (A.B.), Ministry of Health, and the World Health Organization (A.Z.K.) - both in Asmara, Eritrea; the Malaria Genetic and Resistance Unit, INSERM Unité 1201 (L.P., N.P., E.L., D.M.), the Malaria Parasite Biology and Vaccines Unit (L.P., E.L. D.M.), the Bioinformatics and Biostatistics Hub (P.C., A.C.), and the Biomics Platform, Center for Technological Resources and Research (L.M.), Institut Pasteur, Université Paris Cité, and Collège Ecole Doctorale Complexité du Vivant, Sorbonne Université (L.P.), Paris, and the Institute of Parasitology and Tropical Diseases, Dynamics of Host-Pathogen Interactions, Université de Strasbourg (C.D.-L., D.M.), and the Laboratory of Parasitology and Medical Mycology, Centre Hospitalier Universitaire Strasbourg (D.M.), Strasbourg - all in France; the Department of Microbiology and Immunology (B.H.S., K.E.W., D.A.F.) and the Center for Malaria Therapeutics and Antimicrobial Resistance, Division of Infectious Diseases, Department of Medicine (D.A.F.), Columbia University Irving Medical Center, New York; the School of Public Health and Social Medicine, Gothenburg University, Gothenburg, Sweden (M.W.); and the Global Malaria Program, World Health Organization, Geneva (P.R.).
Cécile Doderer-LangFrom the National Malaria Control Program (S.M.) and the Communicable Diseases Control Division (A.B.), Ministry of Health, and the World Health Organization (A.Z.K.) - both in Asmara, Eritrea; the Malaria Genetic and Resistance Unit, INSERM Unité 1201 (L.P., N.P., E.L., D.M.), the Malaria Parasite Biology and Vaccines Unit (L.P., E.L. D.M.), the Bioinformatics and Biostatistics Hub (P.C., A.C.), and the Biomics Platform, Center for Technological Resources and Research (L.M.), Institut Pasteur, Université Paris Cité, and Collège Ecole Doctorale Complexité du Vivant, Sorbonne Université (L.P.), Paris, and the Institute of Parasitology and Tropical Diseases, Dynamics of Host-Pathogen Interactions, Université de Strasbourg (C.D.-L., D.M.), and the Laboratory of Parasitology and Medical Mycology, Centre Hospitalier Universitaire Strasbourg (D.M.), Strasbourg - all in France; the Department of Microbiology and Immunology (B.H.S., K.E.W., D.A.F.) and the Center for Malaria Therapeutics and Antimicrobial Resistance, Division of Infectious Diseases, Department of Medicine (D.A.F.), Columbia University Irving Medical Center, New York; the School of Public Health and Social Medicine, Gothenburg University, Gothenburg, Sweden (M.W.); and the Global Malaria Program, World Health Organization, Geneva (P.R.).
Eric LegrandFrom the National Malaria Control Program (S.M.) and the Communicable Diseases Control Division (A.B.), Ministry of Health, and the World Health Organization (A.Z.K.) - both in Asmara, Eritrea; the Malaria Genetic and Resistance Unit, INSERM Unité 1201 (L.P., N.P., E.L., D.M.), the Malaria Parasite Biology and Vaccines Unit (L.P., E.L. D.M.), the Bioinformatics and Biostatistics Hub (P.C., A.C.), and the Biomics Platform, Center for Technological Resources and Research (L.M.), Institut Pasteur, Université Paris Cité, and Collège Ecole Doctorale Complexité du Vivant, Sorbonne Université (L.P.), Paris, and the Institute of Parasitology and Tropical Diseases, Dynamics of Host-Pathogen Interactions, Université de Strasbourg (C.D.-L., D.M.), and the Laboratory of Parasitology and Medical Mycology, Centre Hospitalier Universitaire Strasbourg (D.M.), Strasbourg - all in France; the Department of Microbiology and Immunology (B.H.S., K.E.W., D.A.F.) and the Center for Malaria Therapeutics and Antimicrobial Resistance, Division of Infectious Diseases, Department of Medicine (D.A.F.), Columbia University Irving Medical Center, New York; the School of Public Health and Social Medicine, Gothenburg University, Gothenburg, Sweden (M.W.); and the Global Malaria Program, World Health Organization, Geneva (P.R.).
Kurt E WardFrom the National Malaria Control Program (S.M.) and the Communicable Diseases Control Division (A.B.), Ministry of Health, and the World Health Organization (A.Z.K.) - both in Asmara, Eritrea; the Malaria Genetic and Resistance Unit, INSERM Unité 1201 (L.P., N.P., E.L., D.M.), the Malaria Parasite Biology and Vaccines Unit (L.P., E.L. D.M.), the Bioinformatics and Biostatistics Hub (P.C., A.C.), and the Biomics Platform, Center for Technological Resources and Research (L.M.), Institut Pasteur, Université Paris Cité, and Collège Ecole Doctorale Complexité du Vivant, Sorbonne Université (L.P.), Paris, and the Institute of Parasitology and Tropical Diseases, Dynamics of Host-Pathogen Interactions, Université de Strasbourg (C.D.-L., D.M.), and the Laboratory of Parasitology and Medical Mycology, Centre Hospitalier Universitaire Strasbourg (D.M.), Strasbourg - all in France; the Department of Microbiology and Immunology (B.H.S., K.E.W., D.A.F.) and the Center for Malaria Therapeutics and Antimicrobial Resistance, Division of Infectious Diseases, Department of Medicine (D.A.F.), Columbia University Irving Medical Center, New York; the School of Public Health and Social Medicine, Gothenburg University, Gothenburg, Sweden (M.W.); and the Global Malaria Program, World Health Organization, Geneva (P.R.).ORCID 0000-0002-3614-436X
Assefash Zehaie KassahunFrom the National Malaria Control Program (S.M.) and the Communicable Diseases Control Division (A.B.), Ministry of Health, and the World Health Organization (A.Z.K.) - both in Asmara, Eritrea; the Malaria Genetic and Resistance Unit, INSERM Unité 1201 (L.P., N.P., E.L., D.M.), the Malaria Parasite Biology and Vaccines Unit (L.P., E.L. D.M.), the Bioinformatics and Biostatistics Hub (P.C., A.C.), and the Biomics Platform, Center for Technological Resources and Research (L.M.), Institut Pasteur, Université Paris Cité, and Collège Ecole Doctorale Complexité du Vivant, Sorbonne Université (L.P.), Paris, and the Institute of Parasitology and Tropical Diseases, Dynamics of Host-Pathogen Interactions, Université de Strasbourg (C.D.-L., D.M.), and the Laboratory of Parasitology and Medical Mycology, Centre Hospitalier Universitaire Strasbourg (D.M.), Strasbourg - all in France; the Department of Microbiology and Immunology (B.H.S., K.E.W., D.A.F.) and the Center for Malaria Therapeutics and Antimicrobial Resistance, Division of Infectious Diseases, Department of Medicine (D.A.F.), Columbia University Irving Medical Center, New York; the School of Public Health and Social Medicine, Gothenburg University, Gothenburg, Sweden (M.W.); and the Global Malaria Program, World Health Organization, Geneva (P.R.).
Pascal RingwaldFrom the National Malaria Control Program (S.M.) and the Communicable Diseases Control Division (A.B.), Ministry of Health, and the World Health Organization (A.Z.K.) - both in Asmara, Eritrea; the Malaria Genetic and Resistance Unit, INSERM Unité 1201 (L.P., N.P., E.L., D.M.), the Malaria Parasite Biology and Vaccines Unit (L.P., E.L. D.M.), the Bioinformatics and Biostatistics Hub (P.C., A.C.), and the Biomics Platform, Center for Technological Resources and Research (L.M.), Institut Pasteur, Université Paris Cité, and Collège Ecole Doctorale Complexité du Vivant, Sorbonne Université (L.P.), Paris, and the Institute of Parasitology and Tropical Diseases, Dynamics of Host-Pathogen Interactions, Université de Strasbourg (C.D.-L., D.M.), and the Laboratory of Parasitology and Medical Mycology, Centre Hospitalier Universitaire Strasbourg (D.M.), Strasbourg - all in France; the Department of Microbiology and Immunology (B.H.S., K.E.W., D.A.F.) and the Center for Malaria Therapeutics and Antimicrobial Resistance, Division of Infectious Diseases, Department of Medicine (D.A.F.), Columbia University Irving Medical Center, New York; the School of Public Health and Social Medicine, Gothenburg University, Gothenburg, Sweden (M.W.); and the Global Malaria Program, World Health Organization, Geneva (P.R.).
David A FidockFrom the National Malaria Control Program (S.M.) and the Communicable Diseases Control Division (A.B.), Ministry of Health, and the World Health Organization (A.Z.K.) - both in Asmara, Eritrea; the Malaria Genetic and Resistance Unit, INSERM Unité 1201 (L.P., N.P., E.L., D.M.), the Malaria Parasite Biology and Vaccines Unit (L.P., E.L. D.M.), the Bioinformatics and Biostatistics Hub (P.C., A.C.), and the Biomics Platform, Center for Technological Resources and Research (L.M.), Institut Pasteur, Université Paris Cité, and Collège Ecole Doctorale Complexité du Vivant, Sorbonne Université (L.P.), Paris, and the Institute of Parasitology and Tropical Diseases, Dynamics of Host-Pathogen Interactions, Université de Strasbourg (C.D.-L., D.M.), and the Laboratory of Parasitology and Medical Mycology, Centre Hospitalier Universitaire Strasbourg (D.M.), Strasbourg - all in France; the Department of Microbiology and Immunology (B.H.S., K.E.W., D.A.F.) and the Center for Malaria Therapeutics and Antimicrobial Resistance, Division of Infectious Diseases, Department of Medicine (D.A.F.), Columbia University Irving Medical Center, New York; the School of Public Health and Social Medicine, Gothenburg University, Gothenburg, Sweden (M.W.); and the Global Malaria Program, World Health Organization, Geneva (P.R.).ORCID 0000-0001-6753-8938
Didier MénardFrom the National Malaria Control Program (S.M.) and the Communicable Diseases Control Division (A.B.), Ministry of Health, and the World Health Organization (A.Z.K.) - both in Asmara, Eritrea; the Malaria Genetic and Resistance Unit, INSERM Unité 1201 (L.P., N.P., E.L., D.M.), the Malaria Parasite Biology and Vaccines Unit (L.P., E.L. D.M.), the Bioinformatics and Biostatistics Hub (P.C., A.C.), and the Biomics Platform, Center for Technological Resources and Research (L.M.), Institut Pasteur, Université Paris Cité, and Collège Ecole Doctorale Complexité du Vivant, Sorbonne Université (L.P.), Paris, and the Institute of Parasitology and Tropical Diseases, Dynamics of Host-Pathogen Interactions, Université de Strasbourg (C.D.-L., D.M.), and the Laboratory of Parasitology and Medical Mycology, Centre Hospitalier Universitaire Strasbourg (D.M.), Strasbourg - all in France; the Department of Microbiology and Immunology (B.H.S., K.E.W., D.A.F.) and the Center for Malaria Therapeutics and Antimicrobial Resistance, Division of Infectious Diseases, Department of Medicine (D.A.F.), Columbia University Irving Medical Center, New York; the School of Public Health and Social Medicine, Gothenburg University, Gothenburg, Sweden (M.W.); and the Global Malaria Program, World Health Organization, Geneva (P.R.).
Malaria Consortium · GBWorld Health Organization - Pakistan · PK
Funding
Defining P. falciparum resistance to artemisinin-based combination therapiesR01AI109023 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI FIDOCK, DAVID A · 2014 to 2025
$4.4MNIAID NIH HHS R01 AI109023NIH HHS R01 AI109023World Health Organization 001
Abstract
backgroundAlthough the clinical efficacy of antimalarial artemisinin-based combination therapies in Africa remains high, the recent emergence of partial resistance to artemisinin in
methodsIn this study, we used data from drug-efficacy studies conducted between 2016 and 2019 that evaluated 3-day courses of artemisinin-based combination therapy (artesunate-amodiaquine or artemether-lumefantrine) for uncomplicated malaria in Eritrea to estimate the percentage of patients with day-3 positivity (i.e., persistent
resultsWe noted an increase in the percentage of patients with day-3 positivity from 0.4% (1 of 273) in 2016 to 1.9% (4 of 209) in 2017 and 4.2% (15 of 359) in 2019. An increase was also noted in the prevalence of the
conclusionsThe emergence and spread of
Indexed as
AntimalarialsArtemether, Lumefantrine Drug CombinationDrug ResistanceMalaria, FalciparumPlasmodium falciparumAmodiaquineAntigens, ProtozoanArtemisininsDrug CombinationsEritreaHumansPrevalenceProtozoan ProteinsAmodiaquineamodiaquine, artesunate drug combinationAntigens, ProtozoanAntimalarialsArtemether, Lumefantrine Drug CombinationArtemisininsDrug CombinationsHRP-2 antigen, Plasmodium falciparumHRP3 protein, Plasmodium falciparumProtozoan Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT07527182ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.